When Could EBR Systems (ASX:EBR) Convert WiSE Implants Into Commercial Revenue?

Sonal Goyal

27 October 2026 12:37 AM AEDT

When Could EBR Systems (ASX:EBR) Convert WiSE Implants Into Commercial Revenue?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

EBR Systems (ASX:EBR) disclosed commercial implants of 40 (46 in 2Q2026) for 3Q2026.
The company reported preliminary quarterly revenue guidance of USD 2.43mn–2.53mn, with versus USD 2.6mn in 2Q2026.
A total of 157 WiSE implants had been completed across the pilot and limited-market release phases; Q3 implant numbers were below earlier forecasts.

EBR Systems (ASX:EBR) operates in implantable cardiac device technology and provides WiSE leadless left-ventricular pacing systems. Its latest material company statement, released on 12 October 2026, describes performance for 3Q2026. The latest operational and financial disclosure is discussed separately from daily share-price trading.

What Did the 12 October 2026 Announcement Report?

In the statement dated 12 October 2026, EBR Systems (ASX:EBR) disclosed commercial implants of 40. The comparison was 46 in 2Q2026. This is a company-reported performance indicator for 3Q2026, and should be read in the context of the company’s business model and the accounting or operating definitions used in the release. The update also identifies preliminary quarterly revenue guidance of USD 2.43mn–2.53mn, with the associated comparison described as versus USD 2.6mn in 2Q2026. Those two measures capture different aspects of performance and are not interchangeable.

Financial Results and Operating Measures

The 3Q2026 release presents commercial implants alongside preliminary quarterly revenue guidance. For EBR Systems (ASX:EBR), reporting both is relevant because the business combines WiSE leadless left-ventricular pacing systems. Revenue and operating indicators describe the level of activity, while earnings or contract-based measures can reflect different timing, costs and recognition methods. The statement records the figures as 40 and USD 2.43mn–2.53mn, respectively. Any comparison with previous reporting periods needs to use the same metric definition and reporting currency.

Operational Developments and Business Execution

A total of 157 WiSE implants had been completed across the pilot and limited-market release phases; Q3 implant numbers were below earlier forecasts. The disclosure sets out the company’s operational priorities and related performance indicators. Contract wins, recurring service delivery, product deployment and customer activity, where relevant, are separate indicators from recognised revenue. The financial outcome depends on the nature and timing of the services or products delivered.

Company Profile and Business Overview

EBR Systems (ASX:EBR) is an Australian-listed business focused on implantable cardiac device technology. Its activities include WiSE leadless left-ventricular pacing systems. The operating model shapes which activity indicators accompany reported earnings, including, where applicable, contract volumes, platform usage, licensing, adoption or project delivery. The 3Q2026 release is therefore most usefully read using the specific figures attributed to EBR Systems (ASX:EBR), without importing metrics from unrelated companies.

Risks and Catalysts on Watch

Commercial training, hospital account utilisation, reimbursement and the preliminary status of revenue guidance remain key factors. The next reported period may also provide additional information on order conversion, customer demand, cash generation, financing, product implementation and the extent to which previously disclosed plans have proceeded. These factors will be reflected in subsequent company updates when further financial or operational information is reported.

Key Insights

The main factual developments for EBR Systems (ASX:EBR) are its 3Q2026 disclosure of commercial implants at 40, the reported preliminary quarterly revenue guidance of USD 2.43mn–2.53mn, and the operational information described above. The publication date was 12 October 2026. These measures should be retained with their precise period and accounting descriptions, especially when comparing the company with other ASX-listed small-cap businesses. Further updates may clarify how operating activity affects subsequently reported earnings and cash flow.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.